AbbVie IncABBV
▲ ポジティブ資本関連度
AbbVie announced a $10.9 billion acquisition of Apogee Therapeutics to expand its immunology portfolio, driving stock to a 52-week high.
資産への影響 2
Biotech & Genomic Medicine
AbbVie Inc
Apogee Therapeutics, Inc. Common StockAPGE
▲ ポジティブ資本関連度
Apogee Therapeutics is being acquired by AbbVie for $10.9 billion, a premium that benefits its shareholders.